Phenotypic intrafamilial variability of 5q-associated spinal muscular atrophy: A systematic multicentre sibling study

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • with SMArtCARE study group - (Author)
  • Department of Neurology
  • Department of Paediatrics, Division of Neuropediatrics
  • Klinikum Rechts der Isar (MRI TUM)
  • University Hospital Aachen
  • Innsbruck Medical University
  • Vienna Healthcare Network
  • Kepler University Hospital
  • University Hospital Münster
  • Saarland University
  • Landeskrankenhaus Bregenz
  • University Hospital Essen
  • University Hospital Gießen and Marburg
  • University Medical Center Göttingen
  • University Hospital Tübingen
  • Medical University of Graz
  • University Hospital Hamburg Eppendorf
  • Rostock University Medical Centre
  • Ruhr University Bochum
  • Catholic Hospital Bochum gGmbH
  • University of Duisburg-Essen
  • Hospital of the Ludwig-Maximilians-University (LMU) Munich
  • Cantonal Hospital St. Gallen
  • Klinikum Klagenfurt am Wörthersee
  • DRK Kliniken Berlin
  • University Hospital at the Friedrich-Alexander University Erlangen-Nürnberg
  • University Hospital Heidelberg
  • German Society for Muscular Dystrophy (DGM)
  • University Medical Center Freiburg

Abstract

Background and objectivesThe severity of the phenotype of spinal muscular atrophy (SMA) is highly variable, yet little is known about the phenotypic variation among siblings. We systematically investigated the phenotypic variability of therapy-naïve 5q-SMA siblings leveraging a large multicentre cohort from the SMArtCARE registry.ResultsClinical information was available from 132 siblings of 65 families. There were 24 (18.2%) type 1, 38 (28.7%) type 2, 54 (40.9%) type 3 patients, and 16 (12.1%) presymptomatic individuals. In 17 families (32.1%), there was discordance in the type of SMA among symptomatic siblings. We found no influence of gender on discordance in SMA type among siblings (p = 0.528). The median age at disease onset within all sibships varied by 6 months (interquartile range (IQR) = 1-30). There was no correlation in age of onset among siblings (r = 0.405; p = 0.052). Among siblings who lost ambulation, the median interval between the start of wheelchair use was 12 months, but the maximal interval was 18 years. In one pair of siblings, one sibling lost the ability to walk at the age of 13, whereas the other sibling was still ambulatory at the age of 54. In 6 sibling pairs (9.5%), only one of both siblings had a history of scoliosis surgery. Analysing SMN2 copy numbers, in one sibling pair (1.8%) 1 SMN2 gene copy was detected, while 10 (17.5%) had 2 copies, 23 (40.4%) had 3 copies, and 17 (29.8%) had 4 copies. Concordance in SMN2 copy numbers across siblings was observed in 90% of families. With increasing SMN2 copy number, the median differences in age of onset among siblings increased without reaching statistical significance.ConclusionThis study reports considerable phenotypic variability in therapy-naïve SMA sibships that cannot solely be explained by differences in SMN2 copy numbers.

Details

Original languageEnglish
Pages (from-to)22143602251370577
JournalJournal of neuromuscular diseases
Publication statusE-pub ahead of print - 12 Sept 2025
Peer-reviewedYes

Keywords